Clinical trials: Chronic Mental Disorders
Schizophrenia, Schizoaffective Disorder
Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder
An open-label, multi-center, 6-week, sequential cohort study designed to determine the safety and tolerability of two dose ranges of BL-1020 in hospitalized subjects with chronic schizophrenia or schizo-affective disorder
- Trial name
- NCT00480571
- Testing
- BL-1020, BL 1020 High Dose
- Where
- 2 sites in Israel, Romania
- Volunteers
- 90 people
- Sponsor
- BioLineRx, Ltd.
Post Acute COVID-19 Syndrome
Digital Health Intervention Based on Artificial Intelligence to Support the Personalized Recovery of Long COVID Patients Affected by Fatigue (AIDA)
The AIDA feasibility study builds upon mental health and technology acceptance theoretical frameworks. It examines the feasibility of a mobile-based digital program to support patients with long covid affected by fatigue.
- Trial name
- AIDA (NCT05483829)
- Testing
- Adhera® Fatigue for Long COVID program
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Adhera Health, Inc.
Opioid-induced Constipation
ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)
The purpose of this study is to assess the safety and tolerability of RDC-1036 (ALKS 37) in adults with opioid-induced constipation (OIC) following repeat dose administration
- Trial name
- NCT01100151
- Testing
- RDC-1036 (ALKS 37)
- Where
- 11 sites in United States
- Volunteers
- 60 people
- Sponsor
- Alkermes, Inc.
Sleep Initiation and Maintenance Disorders
Efficacy of Ramelteon in Subjects With Chronic Insomnia
The purpose of this study is to determine the long-term safety of Ramelteon, once daily (QD), in subjects with chronic insomnia.
- Trial name
- NCT00671086
- Testing
- Ramelteon
- Where
- 122 sites in United States
- Volunteers
- 1,213 people
- Sponsor
- Takeda
Chronic Pain, Depression, Anxiety
Axon - Brain Train for Pain
A mixed methods proof of concept study to ascertain the effectiveness of a home-based self-administered neurofeedback intervention to treat the primary and secondary symptoms of chronic pain.
- Conditions
- Chronic Pain, Depression, Anxiety, Sleep, Quality of Life
- Trial name
- NCT04418362
- Testing
- Neurofeedback training
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Exsurgo Rehab Limited
Posttraumatic Stress Disorder
Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD
The goal of this clinical trial is to learn if MDMA in combination with therapy is safe and effective in people with chronic, treatment-resistant PTSD.
- Trial name
- NCT01793610
- Testing
- Comparator Dose (40mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Active Dose 1 (125 mg) MDMA HCl
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Resilient Pharmaceuticals
Chronic Insomnia
Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia
This purpose of this study is to evaluate the safety and effectiveness of Ramelteon, once daily (QD), in elderly participants with chronic insomnia.
- Trial name
- NCT00671255
- Testing
- Ramelteon
- Where
- 115 sites in United States, Canada
- Volunteers
- 829 people
- Sponsor
- Takeda
Insomnia
A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia
To evaluate the long-term safety and efficacy of eszopiclone administered for 12 weeks in elderly subjects with primary chronic insomnia.Administration of eszopiclone 2 mg daily at bedtime for 12 weeks in elderly subjects with a…
- Trial name
- NCT00386334
- Testing
- Eszopiclone
- Where
- 82 sites in United States
- Volunteers
- 388 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Primary Insomnia
Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia
A 2-night polysomnography / 5-way cross-over study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in elderly subjects with primary insomnia.
- Trial name
- NCT00606593
- Where
- 21 sites in United States
- Volunteers
- 112 people
- Sponsor
- Midnight Pharma, LLC
Opioid-induced Constipation
Assessing a Stool Symptom Screener in Patients With Chronic Opioid-Induced Constipation
This qualitative research is to assess the validity of the stool symptom screener that will be used in patients with chronic opioid-induced constipation to determine the adequacy of their response to laxatives.
- Trial name
- NCT01645371
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
Sleep Initiation and Maintenance Disorders, Mental Disorders
Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)
This trial is a 26-week, open label extension trial to investigate safety and explore efficacy of esmertazapine in participants with insomnia who completed protocol 21106/P05701/MK-8265-002 (NCT00631657).
- Conditions
- Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias, Sleep Disorders
- Trial name
- NCT00750919
- Testing
- esmirtazapine
- Volunteers
- 184 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease, Chronic Traumatic Encephalopathy
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
CMK-0301 is a multi-site, randomized clinical trial to evaluate the safety and efficacy of [F-18]Flornaptitril-PET (F-18 FNT-PET) for the prediction of clinical progression of Mild Cognitive Impairment (MCI) with either Suspected…
- Trial name
- NCT06254469
- Testing
- [F-18]Flornaptitril
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- CereMark Pharma, LLC
Sleep Initiation and Maintenance Disorder; Elderly, Mental Disorder
A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)
The current study is a 52-week safety study in elderly outpatients with chronic primary insomnia randomized to treatment with 1.5 mg or 3.0 mg of esmirtazapine (Org 50081, SCH 900265, MK-8265) to investigate the safety and…
- Conditions
- Sleep Initiation and Maintenance Disorder; Elderly, Mental Disorder, Dyssomnias, Sleep Disorders
- Trial name
- Jade (NCT00561574)
- Testing
- Esmirtazapine
- Volunteers
- 259 people
- Sponsor
- Merck Sharp & Dohme LLC
Pain, Pain Syndrome
Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06072560
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Schizophrenia, Psychotic Disorders
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia
The purpose of the study is to evaluate the effectiveness and safety of different doses of risperidone (an antipsychotic medication) compared with placebo and with a fixed 20 mg/day dose of a standard antipsychotic, haloperidol…
- Trial name
- NCT00249132
- Testing
- risperidone
- Volunteers
- 523 people
- Sponsor
- Janssen, LP
Schizophrenia
A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia
This study will determine the pharmacokinetics (PK), safety, and tolerability of ALKS 9072 (also known as ALKS 9070) after 4 monthly doses in adults with chronic stable schizophrenia.
- Trial name
- NCT01493726
- Testing
- ALKS 9072, Low dose, ALKS 9072, Med dose, ALKS 9072, High dose
- Where
- 6 sites in United States
- Volunteers
- 88 people
- Sponsor
- Alkermes, Inc.
Post-acute COVID-19 Syndrome
SENSING-AI in Patients With Long COVID (SENSING-AI)
The retrospective study will be used to develop an artificial intelligence model of risk stratification of physiological and psychological complications arising from the information available in the electronic medical record and…
- Trial name
- SENSING-AI (NCT06247332)
- Testing
- Review of available clinical data sources related to use cases
- Where
- Spain
- Volunteers
- 103 people
- Sponsor
- Adhera Health, Inc.
Chronic Insomnia, Cancer
Impact of Homeopathy for Persistent Insomnia in Patients With Cancer
Persistent insomnia is highly prevalent complaint in cancer survivors, but is seldom satisfactorily addressed. The adaptation to cancer care of a validated, cost-effective intervention may offer a practicable solution.
- Trial name
- NCT02515006
- Testing
- Homeopathy Medicine
- Where
- 2 sites in India
- Volunteers
- 160 people
- Sponsor
- Adwin Life Care
Pain, Pain Syndrome
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates…
- Conditions
- Pain, Pain Syndrome, Pain, Chronic, Chronic Pain
- Trial name
- NCT06071936
- Testing
- Adezunap (AP707)
- Where
- Germany
- Volunteers
- 558 people
- Sponsor
- Apurano Pharmaceuticals GmbH
Cerebral Palsy, Spasticity
Exopulse Mollii Suit, Motor Functions & CP Children With Cerebral Palsy
Cerebral Palsy (CP) is is estimated to be around 1.5-3 per live birth, with prenatal factors accounting for 75% of cases. CP appears in early childhood and persists with age and is characterized by permanent lesions or…
- Conditions
- Cerebral Palsy, Spasticity, Muscle, Pain Syndrome
- Trial name
- EXOCEP2GER (NCT05885139)
- Testing
- Exopulse Mollii Suit
- Where
- 2 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Exoneural Network AB